DCGI
Latest news and video coverage curated from trusted media outlets
| 0 shares | ShareTweetSavePostSend |
![Indian government bans Common Cold and Flu Syrups for kids below 4 years | Oneindia News [Video]](https://video.newsserve.net/300/v/20231221/1362498000-Indian-government-bans-Common-Cold-and-Flu-Syrups.jpg) Indian government bans Common Cold and Flu Syrups for kids below 4 years | Oneindia News Credit: Oneindia Duration: 03:23Published | |
![DCGI Rec. Message: Local Missions Sunday [Video]](https://video.newsserve.net/300/v/20240121/1705876174-DCGI-Rec-Message-Local-Missions-Sunday.jpg)
You Might Like
DCGI bans all charges, except supply, processing costs on blood unitsThe Drugs Controller General of India (DCI) on Thursday banned all charges except supply and processing costs on blood units.DNA - Published | |
Blood not for sale, charge processing cost only, DCGI tells blood banksDCGI has also asked the drug controller cum licensing authorities to direct all blood centres to adhere to the revised guidelines for recovery of processing charges. When a person donates blood, it is..IndiaTimes - Published | |
MAHE Celebrates Graduates in Grand Convocation Finale*Manipal Academy of Higher Education's (MAHE)* 31^st Convocation concluded on 26^th November. It marked the end of an emotional and joyous four days during which distinguished leaders and guests joined..NewsVoir - Published | |
Breaking Ground in Academia: MAHE Honors Innovators and Researchers at Grand Convocation*Manipal Academy of Higher Education (MAHE)*, an Institution of Eminence, deemed to be University, one of Indias leading research focused educational institutions, held a convocation to discuss various..NewsVoir - Published | |
Rule regulating Ayush ads set to go, but amendments to fill void in limbo for a yearThe Drug Controller General of India (DCGI) has suggested that a rule regulating the advertisement of ayush drugs should only be withdrawn after amendments to the Drugs and Magic Remedies Act are..IndiaTimes - Published | |
DCGI: In case of adverse reaction, don't use Digene gelThe Drug Controller General of India (DCGI) has advised doctors and healthcare professionals to educate their patients to discontinue the use of Digene gel - a commonly prescribed anti-acidity..IndiaTimes - Published | |
DCGI issues advisory against Digene GelnewKerala.com - Published | |
Antacid Digene Gel recalled by Abbott, DCGI issues alert against household medication; know whyDigene Gel, which is used as an antacid in many Indian homes, is now under the radar of the DGCI as an alert has been issued after the product's recall.DNA - Published | |
Warning on common cough syrups; know moreDrugs Controller General of India (DCGI) has warned against the use of pholcodine-containing cold and cough drugs. The warning from the country's drug regulatory authority comes after the World..IndiaTimes - Published | |
After WHO, DCGI issues alert against use of pholcodine-containing cough syrupsWHO warns of anaphylactic risks for those who took pholcodine cough syrups before anesthesia with NMBAs.DNA - Published | |
Intas launches DCGI-approved Tofacitinib Topical (JAKi) in Auto-Immune Condition Atopic Dermatitis (AD) for Indian patientsnewKerala.com - Published | |
India's 1st mRNA Omicron booster vax gets DCGI nod, to launch in 2-3 weeksnewKerala.com - Published | |
Mandatory testing of cough syrup before exports, DCGI asks labs to give top priority to such samplesCough syrup exporters will have to produce a certificate of analysis issued by a government laboratory before the product is exported, effective June 1, the Directorate General of Foreign Trade (DGFT)..IndiaTimes - Published | Covid jab Covovax as heterologous booster to be available on CoWIN soon; to cost Rs 225 per doseCovovax can be administered to those who have already vaccinated with Covishield or Covaxin. The Drugs Controller General of India (DCGI) on January 16 had approved the market authorisation for Covovax..IndiaTimes - Published |
Cabinet clears Rajeev Singh Raghuvanshi's name as new DCGInewKerala.com - Published | Dr PBN Prasad to hold charge as DCGI on temporary basisnewKerala.com - Published |
DCGI approves Keytruda for treatment of cervical cancer: MSDnewKerala.com - Published | Govt to introduce incentive scheme to boost R&D by pharma industry: DCGI SomaniPLI scheme aims to give companies incentives on incremental sales from products manufactured in domestic units.Mid-Day - Published |
Serum Institute seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adultsCovid-19 vaccine India: The Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for adults who have been administered two..Zee News - Published | Covid vaccine news: SII's Covovax approved as heterologous booster dose for adultsDCGI has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults.DNA - Published |
DCGI recommends Covovax as heterologous booster dosenewKerala.com - Published | DCGI approves 14-valent pneumococcal conjugate vaccinenewKerala.com - Published |
Biological E gets DCGI's nod to manufacture, market 14-valent pneumococcal conjugate vaccinenewKerala.com - Published | WHO`s premature linking of Gambia children deaths to Indian cough syrups adversely affected pharma industry`s image: DGCIDrugs Controller General of India (DCGI) Dr V G Somani said a statement issued by WHO in October in the wake of the deaths "was unfortunately amplified by the global media which led to a narrative..Zee News - Published |
DCGI approves '5-arms intranasal hetrologous booster dose' for restricted usenewKerala.com - Published Also reported by •IndiaTimes | Bharat Biotech's Intranasal Covid-19 Booster gets DCGI nod for emergency useFor individuals 18 years of age and older, the DCGI has authorised the use of Bharat Biotech's five arms heterologous booster, ANI reported.DNA - Published |
DCGI chief Dr V G Somani's term extended by 3 monthsnewKerala.com - Published | Biocon Q2FY23 Revenue at Rs. 2,384 Cr., Up 23 percent; Core EBITDA at Rs. 816 Cr., Up 34 percent Gross R&D Spend at Rs. 252 Crore, Up 52 percent *Biocon Ltd.* (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the second quarter ended September 30,..NewsVoir - Published |
DCGI's subject expert committee to hold discussion on 'Five Arms' intranasal heterologous booster dose on Nov 15, sourcesnewKerala.com - Published | Gambia cough syrup deaths: Govt panel says info shared by WHO so far inadequate to determine aetiologyRutendo Kuwana from the WHO on October 13 had written to the DCGI seeking to know the progress with the investigation of the manufacturer of the four cough syrups -- the Sonipat-based Maiden..Zee News - Published |
Gambia children deaths: DCGI seeks more details from WHO to establish causal relationshipThe body said it had shut production in the manufacturing units of the company days.DNA - Published | Cough syrup samples collected, sent for checking: Haryana govt after WHO alertHaryana’s Health Minister Anil Vij said if samples failed to meet the standards, strict action will be taken against the company and its owners. India's drug regulator Drugs Controller General of..Zee News - Published |
Bharat Biotech applies for market authorisation from DCGI for five arms intranasal heterologous boosternewKerala.com - Published | Bharat Biotech seeks DCGI approval for intranasal heterologous boostersThe vaccine development data will be submitted to peer-reviewed journals, "INCOVACC was evaluated to determine its impact on safety.DNA - Published |
India's first intranasal vaccine for Covid gets DCGI approvalnewKerala.com - Published Also reported by •DNA | BREAKING: DCGI gives nod to India’s First Intranasal Covid vaccine for restricted emergency useThe Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far, company sources had said.Zee News - Published |
Corbevax Covid booster expected to get final approval from government soon: ReportEarlier on June 4, DCGI approved Corbevax as a precaution dose for those aged 18 and above.DNA - Published | Bharat Biotech's intranasal Covid-19 vaccine to get DCGI nod soon? Here's what we knowThe Drug Controller General of India gave its nod to conduct clinical trials for BBIL's intranasal vaccine as a booster dose.DNA - Published |
India's first qHPV vaccine against cervical cancer gets DCGI's nodnewKerala.com - Published | |
